Dr. Yongqing Huang is Vice President and Head of Nonclinical Sciences at Arvinas and oversees toxicology, drug metabolism and pharmacokinetics (DMPK), and bioanalysis functions. Dr. Huang joined Arvinas in 2018 after 25 years in the pharmaceutical and biotech industry.
Prior to joining Arvinas, Dr. Huang worked at Achillion Pharmaceutical as Head of DMPK and contributed to the discovery and early development of several oral Factor D inhibitors to treat several complement system-based orphan diseases. Prior to Achillion, Dr. Huang worked as a DMPK scientist at several pharmaceutical companies including Sanofi and Boehringer Ingelheim. Dr. Huang contributed to the nonclinical development of BI 65066, an IL23 MAB inhibitor, which later became Risankizumab and marketed as Skyrizi.
Dr. Huang received his Bachelor of Science in Chemistry from Xiangtan University and his Ph.D. from Purdue University.